PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
PolyPid (Nasdaq: PYPD), a late-stage biopharma company focused on improving surgical outcomes, has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The virtual event is scheduled for February 11-12, 2025.
The company's presentation will be available on-demand starting Wednesday, February 12, 2025, at 11:20 AM Eastern Time and will remain accessible for 365 days through the conference platform. PolyPid's management team will also conduct one-on-one investor meetings during the event. Interested investors can arrange meetings through their Oppenheimer representative.
PolyPid (Nasdaq: PYPD), un'azienda biofarmaceutica in fase avanzata focalizzata sul miglioramento dei risultati chirurgici, ha annunciato la sua partecipazione alla 35ª Conferenza Annuale di Oppenheimer sulle Scienze della Vita e della Salute. L'evento virtuale è programmato per l'11-12 febbraio 2025.
La presentazione dell'azienda sarà disponibile on-demand a partire da mercoledì 12 febbraio 2025, alle 11:20 ET e rimarrà accessibile per 365 giorni attraverso la piattaforma della conferenza. Il team di gestione di PolyPid condurrà anche meeting individuali con gli investitori durante l'evento. Gli investitori interessati possono organizzare incontri tramite il proprio rappresentante di Oppenheimer.
PolyPid (Nasdaq: PYPD), una empresa biofarmacéutica en etapa avanzada centrada en mejorar los resultados quirúrgicos, ha anunciado su participación en la 35ª Conferencia Anual de Ciencias de la Salud de Oppenheimer. El evento virtual está programado para el 11 y 12 de febrero de 2025.
La presentación de la empresa estará disponible a demanda a partir del miércoles 12 de febrero de 2025, a las 11:20 AM Hora del Este y seguirá accesible durante 365 días a través de la plataforma de la conferencia. El equipo de gestión de PolyPid también llevará a cabo reuniones individuales con inversores durante el evento. Los inversores interesados pueden coordinar reuniones a través de su representante de Oppenheimer.
PolyPid (Nasdaq: PYPD), 수술 결과 개선에 중점을 둔 후기 단계의 생명공학 회사가 오펜하이머 제35회 연례 의료 생명과학 컨퍼런스에 참여한다고 발표했습니다. 가상 이벤트는 2025년 2월 11일부터 12일까지 예정되어 있습니다.
회사의 발표는 2025년 2월 12일 수요일 동부 표준시 기준 오전 11:20부터 주문형으로 제공되며, 컨퍼런스 플랫폼을 통해 365일 동안 접근할 수 있습니다. PolyPid의 경영팀은 또한 이벤트 중에 투자자와의 일대일 회의를 진행할 것입니다. 관심 있는 투자자는 자신의 오펜하이머 대표를 통해 회의를 조정할 수 있습니다.
PolyPid (Nasdaq: PYPD), une entreprise biopharmaceutique en phase avancée axée sur l'amélioration des résultats chirurgicaux, a annoncé sa participation à la 35e Conférence Annuelle Oppenheimer sur les Sciences de la Vie et de la Santé. L'événement virtuel est prévu pour les 11 et 12 février 2025.
La présentation de l'entreprise sera disponible à la demande à partir du mercredi 12 février 2025 à 11h20 heure de l'Est et restera accessible pendant 365 jours via la plateforme de la conférence. L'équipe de direction de PolyPid mènera également des réunions individuelles avec des investisseurs pendant l'événement. Les investisseurs intéressés peuvent organiser des réunions par l'intermédiaire de leur représentant Oppenheimer.
PolyPid (Nasdaq: PYPD), ein Unternehmen der biopharmazeutischen Industrie in der späten Phase, das sich auf die Verbesserung der chirurgischen Ergebnisse konzentriert, hat seine Teilnahme an der 35. Jahrestagung für Gesundheits- und Lebenswissenschaften von Oppenheimer bekannt gegeben. Die virtuelle Veranstaltung ist für den 11. und 12. Februar 2025 angesetzt.
Die Präsentation des Unternehmens wird ab Mittwoch, den 12. Februar 2025, um 11:20 Uhr Eastern Time on-demand verfügbar sein und bleibt für 365 Tage über die Konferenzplattform zugänglich. Das Management-Team von PolyPid wird auch persönliche Investorengespräche während der Veranstaltung führen. Interessierte Investoren können über ihren Oppenheimer-Vertreter Meetings vereinbaren.
- None.
- None.
PETACH TIKVA, Israel, Jan. 30, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that the Company’s management will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference taking place virtually on February 11 - 12, 2025.
Oppenheimer 35th Annual Healthcare Life Sciences Conference
PolyPid’s presentation will be available on-demand beginning on Wednesday, February 12, 2025 at 11:20 AM Eastern Time and for 365 days after via the conference platform or using the following link.
The PolyPid management team will participate in one-on-one investor meetings during this event. Investors interested in meeting with PolyPid at the conference should contact their Oppenheimer representative.
About PolyPid
PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX100 is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma.
For additional Company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn.
Contacts:
PolyPid Ltd.
Ori Warshavsky
COO – US
908-858-5995
IR@Polypid.com
Investors:
Brian Ritchie
LifeSci Advisors
212-915-2578
britchie@lifesciadvisors.com
FAQ
When is PolyPid (PYPD) presenting at the Oppenheimer Healthcare Conference 2025?
How long will PolyPid's (PYPD) Oppenheimer Conference presentation be available to view?
Is the Oppenheimer Healthcare Conference 2025 where PYPD is presenting in-person or virtual?
How can investors arrange meetings with PolyPid (PYPD) management at the Oppenheimer Conference?
What are the dates for the Oppenheimer Healthcare Conference 2025 featuring PYPD?
